Q3 Earnings Forecast for REGN Issued By Leerink Partnrs

Key Points

• Analysts at Leerink Partners raised their Q3 2025 earnings per share estimate for Regeneron Pharmaceuticals from $7.64 to $7.77.
• Regeneron Pharmaceuticals reported a Q2 EPS of $12.89, significantly exceeding the consensus estimate of $8.43, alongside a revenue of $3.68 billion.
• Currently, the market consensus includes a rating of "Moderate Buy" with a target price of $817.67, and the company has a strong institutional ownership of 83.31%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings per share of $7.77 for the quarter, up from their previous forecast of $7.64. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' FY2025 earnings at $31.96 EPS.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period last year, the company posted $11.56 earnings per share. The firm's revenue was up 3.6% compared to the same quarter last year.

A number of other brokerages have also issued reports on REGN. Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Royal Bank Of Canada lifted their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research report on Monday, August 4th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price on the stock. Finally, Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Up 6.7%

Shares of NASDAQ REGN opened at $599.94 on Thursday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,045.95. The firm has a market cap of $63.59 billion, a price-to-earnings ratio of 15.12, a PEG ratio of 1.79 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock's 50-day simple moving average is $570.67 and its 200-day simple moving average is $568.93.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caldwell Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $51,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $31,000. Valeo Financial Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 51.3% during the second quarter. Valeo Financial Advisors LLC now owns 1,797 shares of the biopharmaceutical company's stock worth $944,000 after buying an additional 609 shares during the period. Osaic Holdings Inc. raised its holdings in Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company's stock worth $9,607,000 after purchasing an additional 6,073 shares in the last quarter. Finally, MASTERINVEST Kapitalanlage GmbH bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $1,138,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.